Recurrent breast cancer
Conditions
Interventions
high-dose toremifene 120mg/body
Sponsors
Hiroshima Breast Cancer Study Group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Case confirmed by pathological diagnosis. 2. Postmenopausal women with breast cancer by mastectomy or breast conserving surgery. 3. Recurrent breast cancer patients who are taking anastorozole or letrozole as an adjuvant therapy. 4. Recurrent breast cancer patients who have finished anastorozole or letrozole as an adjuvant therapy less than 1 year ago. 5. Case with measurable primary lesions. 6. Case with positive ER or PgR. 7. Case with PS 0 or 1. 8. Case with a satisfactory function of a heart liver kidney bone marrow ant to satisfy the next condition. 9. Case stopped anastorozole or letrozole more than 2 weeks ago. 10. Case that last menstration was observed more than 1 year ago. 11. Case that survival more than 3 months is anticipated. 12. Case signedinformed consent of the patients for the registration.
Exclusion criteria
Exclusion criteria: (1)Contraindication case for toremifene. (2)Case with inflammatory breast cancer or bilateral breast cancer. (3)Case with active other malignancies. (4)Case with life-threatening metastasis. (5)Case with past history of drug allergy or hypersensitivity. (6)Case with past use of anti-estrogen drug. (7)Case judged inappropriate by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| .Clinical benefit .Response Rate (CR, PR) | — |
Secondary
| Measure | Time frame |
|---|---|
| .TTP(Time to progression) .TTF(Time to treatment failure) | — |
Countries
Japan
Contacts
Public ContactShoichiro Ohtani
Hiroshima Breast Cancer Study Group Hiroshima Cancer Support
Outcome results
None listed